Kailera Therapeutics, Inc. KLRA
- Market cap
- $1.6B
- P/E
- 0.0×
Follow KLRA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 145 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | 0 | (149) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | 0 | (149) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | — | (949.00) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | (601,050.00) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | (10,440.00) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | (611,490.00) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 3,179,530.00 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | 0 | (120) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | (2) |
Capex
|
|||
| — | — | — | — | — | — | — | — | 0 | (122) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 171 | 511 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (175) | (546) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 172 | 636 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | — | (34.21%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (110.14%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | — | 51.79% |
ROE
|
|||
Kailera Therapeutics, Inc. (KLRA) Latest News
18 Aug
Kailera Therapeutics completes record-breaking obesity IPO that draws immediate Big Pharma attention and capital inflows. Record IPO supplies transformative capital and visibility that redefines Kailera's competitive position in obesity drugs.
12 Aug
Kailera Therapeutics reported second quarter 2026 financial results and provided business updates. Quarterly financial results and updates offer performance data that can shift near-term investor views and valuation.
10 Jul
Kailera Therapeutics (KLRA) stands out as one of the best IPO stocks with huge upside potential. Positive positioning of KLRA as a top IPO stock can lift near-term investor sentiment and trading activity.
8 Jul
Kailera Therapeutics weight loss pill trials showed nausea as a major side effect, leading to a stock price decline. Negative trial results on nausea side effects directly harm Kailera's weight loss drug development and investor confidence.
7 Jul
Kailera Therapeutics announced that its oral small molecule KAI-7535 achieved up to 11% weight loss in a Phase 3 trial. Positive Phase 3 data for lead obesity candidate signals major commercial upside and valuation surge.
Kailera Therapeutics' IPO setback drives further gains in Eli Lilly's market cap. IPO setback directly delays KLRA funding and market entry.
Kailera Therapeutics reports oral small molecule KAI-7535 achieved up to 11% weight loss in Phase 3 trial, triggering share decline. Phase 3 success for lead obesity candidate drives major trajectory shift via regulatory and commercial potential.
Kailera Therapeutics obesity pill succeeds in late-stage trial in China. Positive late-stage trial result for core obesity drug directly strengthens development pipeline and investor outlook.
Kailera Therapeutics announces positive topline data from two Hengrui Pharma Phase 3 clinical trials of oral small molecule GLP-1 receptor agonist HRS-7535/KAI-7535. Positive Phase 3 data on oral GLP-1 agonist advances regulatory path and commercial positioning.
2 Jul
Pfizer CEO highlights company's large balance sheet for acquisitions and names Kailera Therapeutics as ideal next target. Pfizer CEO's acquisition comments directly elevate Kailera as a takeover candidate with major valuation upside.
5 Jun
Hengrui Pharma and Kailera Therapeutics presented ribupatide clinical data at ADA 2026. Ribupatide clinical data presentation at major diabetes conference signals major pipeline progress for Kailera.
26 May
Kailera Therapeutics reported first quarter 2026 financial results and clinical data updates. Quarterly financial results combined with clinical data updates typically drive major shifts in biotech valuation and investor outlook.
13 May
Analyst notes Kailera Therapeutics could replicate Eli Lilly's weight-loss drug strategy for market gains. Analyst commentary on strategy mimicry may lift near-term sentiment but lacks confirmed major developments.